FDA approves subcutaneous version of Bristol Myers' Opdivo

A decade after Bristol Myers Squibb first won approval for its PD-1 checkpoint inhibitor Opdivo, the cancer drug has been approved in a subcutaneous form that's becoming a new area of competition for the blockbuster ...